SpringerLink
Log in

High Propensity to Switch to Long-acting Injectable HIV PrEP with Cabotegravir in a Cohort of Oral PrEP Experienced Men who Have Sex with Men in Italy

  • Original Paper
  • Published:
AIDS and Behavior Aims and scope Submit manuscript

Abstract

Aim was to investigate the propensity to switch to long-acting injectable HIV pre-exposure prophylaxis (PrEP) with cabotegravir among oral PrEP-experienced men who have sex with men. Out of 377 PrEP users, 325 (86.2%) were interested (would like = 210) or considering (would consider = 115) switch to long-acting PrEP. At multivariable analysis, the odds ratio of interest in long-acting PrEP in non-adherent vs. adherent individuals to oral PrEP was 5.03 (95%CI = 1.73–14.61,p = 0.003) and of consideration 1.63 (95%CI = 0.51–5.23,p = 0.410). We observed very high propensity to switch to long-acting PrEP, particularly among non-adherent users. Rapid availability of long-acting PrEP might address unmet needs of PrEP users in Italy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price includes VAT (Canada)

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

Abbreviations

PrEP:

Pre exposure prophylaxis

STI:

Sexually transmitted infection

References

  1. Landovitz RJ, Donnell D, Clement ME, Hanscom B, Cottle L, Coelho L, et al. Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. N Engl J Med. 2021;385(7):595–608. https://doi.org/10.1056/NEJMoa2101016.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Molina JM, Ghosn J, Assoumou L, Delaugerre C, Algarte-Genin M, Pialoux G, et al. Daily and on-demand HIV pre-exposure prophylaxis with emtricitabine and tenofovir disoproxil (ANRS PREVENIR): a prospective observational cohort study. Lancet HIV. 2022;9(8):e554–62. https://doi.org/10.1016/S2352-3018(22)00133-3.

    Article  CAS  PubMed  Google Scholar 

  3. McCormack S, Dunn DT, Desai M, Dolling DI, Gafos M, Gilson R, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet. 2016;387(10013):53–60. https://doi.org/10.1016/S0140-6736(15)00056-2.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Ambrosioni J, Petit E, Liegeon G, Laguno M, Miró JM. Primary HIV-1 infection in users of pre-exposure prophylaxis. Lancet HIV. 2021;8(3):e166–74. https://doi.org/10.1016/S2352-3018(20)30271-X.

    Article  CAS  PubMed  Google Scholar 

  5. Girometti N, McCormack S, Tittle V, McOwan A, Whitlock G, 56 Dean Street Collaborative Group. Rising rates of recent preexposure prophylaxis exposure among men having sex with men newly diagnosed with HIV: antiviral resistance patterns and treatment outcomes. AIDS. 2022;36(4):561–6. https://doi.org/10.1097/QAD.0000000000003143.

    Article  CAS  PubMed  Google Scholar 

  6. Jourdain H, de Gage SB, Desplas D, Dray-Spira R. Real-world effectiveness of pre-exposure prophylaxis in men at high risk of HIV infection in France: a nested case-control study. Lancet Public Health. 2022;7(6):e529–36. https://doi.org/10.1016/S2468-2667(22)00106-2.

    Article  PubMed  Google Scholar 

  7. Overton ET, Richmond G, Rizzardini G, Jaeger H, Orrell C, Nagimova F, et al. Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2 M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. Lancet. 2021;396(10267):1994–2005. https://doi.org/10.1016/S0140-6736(20)32666-0.

    Article  PubMed  Google Scholar 

  8. Akinwunmi B, Buchenberger D, Scherzer J, Bode M, Rizzini P, Vecchio F, et al. Factors associated with interest in a long-acting HIV regimen: perspectives of people living with HIV and healthcare providers in four european countries. Sex Transm Infect. 2021;97(8):566–73. https://doi.org/10.1136/sextrans-2020-054648.

    Article  PubMed  Google Scholar 

  9. Alberton F, Nozza S, Raccagni AR, Galli L, Spagnuolo V, Bossolasco S, et al. The propensity for long-acting cabotegravir and rilpivirine every 2 months among HIV-infected people eligible for treatment. J Med Virol. 2023;95(1):e28330. https://doi.org/10.1002/jmv.28330.

    Article  CAS  PubMed  Google Scholar 

  10. Fonner VA, Ridgeway K, van der Straten A, Lorenzetti L, Dinh N, Rodolph M, et al. Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition. AIDS. 2023;37(6):957–66. https://doi.org/10.1097/QAD.0000000000003494.

    Article  CAS  PubMed  Google Scholar 

  11. Smith DK, Pals SL, Herbst JH, Shinde S, Carey JW. Development of a clinical screening index predictive of incident HIV infection among men who have sex with men in the United States. J Acquir Immune Defic Syndr. 2012;60(4):421–7. https://doi.org/10.1097/QAI.0b013e318256b2f6.

    Article  PubMed  Google Scholar 

  12. Schoenberg P, Edwards OW, Merrill L, Martinez CA, Stephenson R, Sullivan PS, et al. Willingness to use and preferences for long-acting injectable PrEP among sexual and gender minority populations in the southern United States, 2021–2022: cross-sectional study. J Int AIDS Soc. 2023;26(3):e26077. https://doi.org/10.1002/jia2.26077.

    Article  PubMed  PubMed Central  Google Scholar 

  13. Jones MD, Jones K, Almirol E, Payne G, Graves B, Schneider JA, et al. Examining the awareness, acceptability, and adoption of conventional and non-conventional forms of Pre-Exposure Prophylaxis (PrEP) for HIV Prevention among jail-involved black sexual minority men (BSMM) and black Transgender Women (BTW) in two diverse US Cities. AIDS Behav. 2023;27(4):1304–13. https://doi.org/10.1007/s10461-022-03866-4.

    Article  PubMed  Google Scholar 

  14. Pedrana L, Magno L, Zucchi EM, da Silva LAV, Ferraz D, Grangeiro A, et al. Zero knowledge and high interest in the use of long-acting injectable pre-exposure prophylaxis (PrEP) among adolescent men who have sex with men and transgender women in two capital cities in Brazil. BMC Public Health. 2022;22(1):1728. https://doi.org/10.1186/s12889-022-14134-4.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Beckham SW, Mantsios A, Galai N, Likindikoki S, Mbwambo J, Davis W, Kerriet al, et al. Acceptability of multiple modalities of pre-exposure prophylaxis (PrEP) among female sex workers in Tanzania: a mixed-methods study. BMJ Open. 2022;12(8):e058611. https://doi.org/10.1136/bmjopen-2021-058611.

    Article  PubMed  PubMed Central  Google Scholar 

  16. Ogunbajo A, Tsai AC, Kanki PJ, Mayer KH. Acceptability of and Preferences for Long-Acting Injectable HIV PrEP and other PrEP modalities among sexual minority men in Nigeria, Africa. AIDS Behav. 2022;26(7):2363–75. https://doi.org/10.1007/s10461-022-03575-y.

    Article  PubMed  Google Scholar 

  17. John SA, Zapata JP, Dang M, Pleuhs B, O’Neil A, Hirshfield S, et al. Exploring preferences and decision-making about long-acting injectable HIV pre-exposure prophylaxis (PrEP) among young sexual minority men 17–24 years old. Sci Rep. 2023;13(1):5116. https://doi.org/10.1038/s41598-023-32014-8.

    Article  ADS  CAS  PubMed  PubMed Central  Google Scholar 

  18. Torres TS, Nascimento AR, Coelho LE, Konda KA, Vega-Ramirez EH, Elorreaga OA, et al. Preferences for PrEP modalities among gay, bisexual, and other men who have sex with men from Brazil, Mexico, and Peru: a cross-sectional study. Ther Adv Infect Dis. 2023;10:20499361231153548. https://doi.org/10.1177/20499361231153548.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Wray TB, Chan PA, Klausner JD, Ward LM, Ocean EMS. Gay, bisexual, and other men who have sex with Men who are not on oral PrEP may be less interested in available Injectable Products than in oral PrEP: examining individual-level determinants of interest and barriers across products. AIDS Behav. 2022;26(11):3794–805. https://doi.org/10.1007/s10461-022-03708-3.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Chan C, Vaccher S, Fraser D, Grulich AE, Holt M, Zablotska-Manos I, et al. Preferences for current and future PrEP modalities among PrEP-Experienced gay and bisexual men in Australia. AIDS Behav. 2022;26(1):88–95. https://doi.org/10.1007/s10461-021-03344-3.

    Article  PubMed  Google Scholar 

Download references

Acknowledgements

A.R.R. performed the surveys, visited individuals and contributed to writing the article. C.C. and B.T. contributed to reviewing the article. M.F.L. contributed to the collection of clinical data and to writing the article. G.P. contributed to writing the article. E.M. and N.G. and contributed to the reviewing of the article. S.N. designed the study, visited individuals and contributed to the writing of the article. A.C. coordinated clinical activities and contributed to the reviewing of the article. L.G. performed analyses and contributed to the writing of the article. R.L. collected data. All authors have read and agreed to the published version of the manuscript.

Funding

None.

Author information

Authors and Affiliations

  1. Vita-Salute San Raffaele University, Via Stamira D’Ancona 20, Milano, 20127, Italy

    Angelo Roberto Raccagni, Maria Francesca Lucente, Caterina Candela, Benedetta Trentacapilli, Giacomo Ponta, Antonella Castagna & Silvia Nozza

  2. Infectious Diseases Unit, San Raffaele Scientific Institute, Milan, Italy

    Laura Galli, Riccardo Lolatto, Emanuela Messina, Nicola Gianotti, Antonella Castagna & Silvia Nozza

Authors
  1. Angelo Roberto Raccagni
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Laura Galli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Maria Francesca Lucente
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Caterina Candela
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Riccardo Lolatto
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Benedetta Trentacapilli
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Giacomo Ponta
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Emanuela Messina
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Nicola Gianotti
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Antonella Castagna
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Silvia Nozza
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Angelo Roberto Raccagni.

Ethics declarations

Conflict of Interest

None to disclose.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Electronic Supplementary Material

Below is the link to the electronic supplementary material.

Supplementary Material 1

Supplementary Material 2

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Raccagni, A.R., Galli, L., Lucente, M.F. et al. High Propensity to Switch to Long-acting Injectable HIV PrEP with Cabotegravir in a Cohort of Oral PrEP Experienced Men who Have Sex with Men in Italy. AIDS Behav 28, 907–911 (2024). https://doi.org/10.1007/s10461-023-04197-8

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10461-023-04197-8

Keywords

Search

Navigation